Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02168829Phase 4Completed

Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Role: collaborator

NCT03110627Not ApplicableUnknown

Increasing Detection of Sub-Clinical Atrial Fibrillation in Defibrillator Patients With the Use of a VDD-ICD Lead

Role: collaborator

NCT01928498Not ApplicableCompleted

Drug Eluting Balloon for Prevention of Hemodialysis Access Restenosis

Role: collaborator

NCT01880242Completed

BIOFLOW-III Canada Satellite Registry

Role: lead

NCT03049722Not ApplicableCompleted

Clinical Investigation Plan for the AVOPT Data Collection Clinical Study

Role: lead

All 5 trials loaded